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758ischemic or hemorrhagic stroke, or a ventricular
arrhythmia (4). Social factors such as isolation and
lack of human support also affect the incidence of
cardiovascular disease. The economically less well-off
classes are at a disadvantage regarding many diseases,
including cancer and cardiovascular disease. And
ﬁnally, it has been proved that even spiritual factors,
such as religiosity, not only are able to inﬂuence how
the patient faces and tolerates the disease, but also are
associated with prolonged survival (5).
A medicine that is essentially technological fails to
take into consideration the personal aspect, namely
how the patient lives with his or her illness. The impact
of a disease on family, work, sexual, and emotional life
as well as the patient’s self-image is not explored in
present-daymedicine, and doctors often totally ignore
the personal dimension of their patients. Medicine is
certainly very complex, and technology helps us shed
light into this abyss for better patient care, but the
patient is even more complex. However, we should
consider many more variables than we usually do.
Finally, the integration of medicine at the bedside and
technology could reduce the number of inappropriate
examinations, and thus healthcare costs.
For Marcuse, man had to break free from the con-
straints of a technological civilization to achieve
freedom, and this freedom would have to be achieved
mostly through the imagination (l’imagination au
pouvoir). Unfortunately, the patient cannot free
himself or herself alone from the dimension to which
he or she has been relegated; this is the duty of
physicians. As suggested by Dr. Fuster, without
sacriﬁcing our technological progress, physicians
must rediscover the human dimension of patients,
their fragility faced with the disease and their anxi-
eties; they should spend more time communicating
with their patients, resume the habit of performing a
physical examination as complete as possible, better
understand nonverbal body language, and, ﬁnally,
consider themselves an integral part of the cure.*Daniele Rovai, MD
Franco Bonaguidi, DPsych
*National Research Council
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1158–63.Characteristic LV Regional
Wall Motion Abnormality
Sign of Cardiotoxicity?I read with interest the State-of-the-Art Paper by
Thavendiranathan et al. (1).
I would like to ask the authors if they have noticed
characteristic regional wall motion pattern in dilated
cardiomyopathy-inferoposterior akinesia with pre-
served contractility in proximal third of the posterior
wall, together with various degree of hypocon-
tractility in the remaining left ventricle. It would be of
interest to answer when this pattern occurs in the
course of cardiomyopathy development and if it is
preceded by inferior wall hypokinesis. What is the
recovery potential if chemotherapy is stopped and
cardioprotective medications instituted immediately
after the recognition of these simple and quickly
acquirable parameters?*Niksa Drinkovic, Jr, MD
*University Hospital Centre Zagreb
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Wall Motion Abnormality
Sign of Cardiotoxicity?We thank Dr. Drinkovic for the interest in our State-
of-the-Art Paper (1). Studies based on histology (2),
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759echocardiography, and/or nuclear imaging (3) all
recognize the possibility of regional involvement
from cardiotoxicity. Abnormal regional myocardial
strain assessment—which is more sensitive for iden-
tifying regional functional abnormalities than visual
assessment alone—has been described, particularly
with anthracycline therapy (4). However, none of
these studies has reported a consistent pattern of
regional wall motion abnormalities. Additionally, we
are unaware of publications that have demonstrated a
relationship between a particular regional pattern of
wall motion abnormalities with cardiomyopathy or
heart failure.
In clinical practice, we have not noticed the
speciﬁc pattern of inferolateral wall motion abnor-
mality mentioned by Dr. Drinkovic, although we
have not evaluated this systematically. Nonetheless,
the occurrence of visibly detectable regional wall
abnormalities during cancer chemotherapy may
signify signiﬁcant myocardial injury and may be
associated with a reduction in left ventricular ejec-
tion fraction. Whether management decisions based
on such ﬁndings will improve outcomes such as the
development of heart failure is unknown. Studies
focused on a regional approach are likely to be
limited by the impact of artifact and apparently
random variation of regional strain values, as well
as the known interobserver variation of regional
wall motion assessment. At present, the expert
consensus document on multimodality imaging
evaluation of adult patients during and after ther-
apy proposes changes of global strain to deﬁne
cardiotoxicity (5).*Paaladinesh Thavendiranathan, MD, MSc
Thomas H. Marwick, MD, PhD, MPH
*Peter Munk Cardiac Center
Toronto General Hospital
200 Elizabeth Street
Toronto, Ontario, M5G 2C4
Canada
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911–39.Statin Dose Based on
Limited EvidenceThe review by Smith and Grundy (1) of the American
College of Cardiology/American Heart Association
Cholesterol Treatment Guideline is helpful, but rec-
ommendations for statin dosing are not supported by
robust evidence. Simvastatin is routinely available in
a 16-fold range of strengths (5 to 80 mg) but the
relationship between statin dose and outcomes re-
mains controversial. When allowance is made for the
efﬁcacies of the different statins (2), an audit of
Western Australian pharmacies disclosed a 64-fold
range in statin dose prescribed. Statin dose has
important consequences for individual patient out-
comes: avoidable cardiovascular events with insufﬁ-
cient dose, unnecessary side effects with excessive
dose.
Compared with the reduction in low-density lipo-
protein (LDL) cholesterol with the maximum dose of
atorvastatin, 80 mg daily, the effective dose that
lowers LDL by 50%, the ED50, is about 3 mg (2). A
dose of 20 mg daily is near the top of the dose
response curve and likely to be sufﬁcient for most
patients. The relationship with coronary events
weakens with lower levels of cholesterol (3). The
reduction in mortality seen with only 20 to 40 mg of
simvastatin in the Heart Protection Study was inde-
pendent of the fall in serum cholesterol. Clinicians
should probably avoid unnecessarily high statin
doses that increase side effects without meaningful
additional clinical beneﬁt.
Higher dosing is partly driven by small acute cor-
onary studies, which by 3 months demonstrate only a
marginal beneﬁt. The beneﬁt of statin therapy in
meta-analysis even after 1 year is only one third
of that seen by 5 years (2). Atorvastatin 10 mg
daily, compared with placebo, reduces serum LDL
cholesterol by around 40% (1.8 mmol/l) and after 3
years reduces coronary events upward of 40% (2).
The effects of different doses of a statin on outcome
were best addressed in the TNT (Treating to New
Targets) study, in which increasing the dose of ator-
vastatin 8-fold, from 10 to 80 mg daily, had no impact
